Followers | 16 |
Posts | 1978 |
Boards Moderated | 30 |
Alias Born | 08/11/2021 |
Tuesday, August 08, 2023 1:44:02 PM
Recent NRBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/04/2024 01:30:23 PM
- NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH • PR Newswire (US) • 11/04/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/07/2024 11:00:29 AM
- NeuroBo Pharmaceuticals to Participate in Investor Conferences in October • PR Newswire (US) • 10/01/2024 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/30/2024 12:07:00 PM
- NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity • PR Newswire (US) • 09/30/2024 12:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/20/2024 08:20:16 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 09/20/2024 08:15:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2024 08:10:30 PM
- NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference • PR Newswire (US) • 09/03/2024 12:01:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/21/2024 08:02:05 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 09:08:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:01:18 PM
- NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 08/14/2024 12:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 12:30:30 PM
- NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity • PR Newswire (US) • 08/13/2024 12:01:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/07/2024 12:00:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 12:30:17 PM
- NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity • PR Newswire (US) • 08/06/2024 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 12:30:18 PM
- NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01 • PR Newswire (US) • 07/30/2024 12:01:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/25/2024 04:15:06 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/24/2024 09:11:14 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/18/2024 12:21:15 PM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • NBRI • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM